79398-27-9

Basic information

• Product Name: Methyl 4,6-dihydroxynicotinate
• Synonyms: methyl 6-hydroxy-4-oxo-1H-pyridine-3-carboxylate;Methyl 4,6-dihydroxynicotinate;3-Pyridinecarboxylic acid, 1,6-dihydro-4-hydroxy-6-oxo-, Methyl ester;Methyl 4,6-dihydroxypyridine-3-carboxylate;Methyl 4,6-dihydroxypyridine-3-carboxylate, 2,4-Dihydroxy-5-(methoxycarbonyl)pyridine;methyl 4-hydroxy-6-oxo-1,6-dihydropyridine-3-carboxylate;4,6-Dihydroxy-nicotinic acid methyl ester;EOS-61393
• CAS NO: 79398-27-9
• Molecular Formula: C₇H₇NO₄
• Molecular Weight: 169.13
• Mol File: 79398-27-9.mol
• Article Data: 11

Chemical Properties

• Melting Point: 252-255°
• Boiling Point: 325.9 ºC at 760 mmHg
• Flash Point: 150.9 ºC
• Appearance: /
• Density: 1.456 g/cm³
• Vapor Pressure: 1.71E-05mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 4.50±1.00(Predicted)
• CAS DataBase Reference: Methyl 4,6-dihydroxynicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4,6-dihydroxynicotinate(79398-27-9)
• EPA Substance Registry System: Methyl 4,6-dihydroxynicotinate(79398-27-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 79398-27-9(Hazardous Substances Data)

Usage

General Description

Methyl 4,6-dihydroxynicotinate, also known as MeDHNA, is a chemical compound derived from nicotinic acid, a form of vitamin B3. It is commonly used as an ingredient in cosmetic and personal care products due to its antioxidant properties and ability to promote skin hydration. MeDHNA is also known for its anti-inflammatory and anti-aging effects, making it a popular ingredient in skincare formulations. Additionally, it has been studied for its potential role in the treatment of neurological disorders and cardiovascular diseases. Overall, MeDHNA has a wide range of potential applications in the fields of health and wellness, making it a versatile and valuable chemical compound.

InChI:InChI=1/C7H7NO4/c1-12-7(11)4-3-8-6(10)2-5(4)9/h2-3H,1H3,(H2,8,9,10)

Upstream product

• 17094-36-9 dimethyl acetylmalonate 
• 149-73-5 trimethyl orthoformate 
• 610271-66-4 dimethyl 2-[(dimethylamino)methylidene]-3-oxopentane-1,5-dioate 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 122-51-0 orthoformic acid triethyl ester 
• 61043-19-4 2-[1-Ethoxy-meth-(Z)-ylidene]-3-oxo-pentanedioic acid dimethyl ester 

Downstream Products

• 1060811-62-2 2,4-dichloro-5-pyridinecarboxaldehyde 
• 1206979-33-0 6-chloro-1H-pyrazolo[4,3-c]pyridine 
• 1263059-66-0 (6-chloro-4-methoxypyridin-3-yl)methanol 
• 1256823-05-8 6-chloro-4-methoxypyridine-3-carbaldehyde 
• 905563-73-7 4,6-dimethoxy-nicotinic acid methyl ester 
• 1093955-41-9 C₁₀H₁₃ClN₂O₃ 
• 887572-34-1 2-chloro-4-ethoxypyridine-5-carboxylic acid 
• 73027-79-9 4,6-dichloro-nicotinic acid 

Relevant articles and documents

Preparation method of 6-chloro-4-hydroxypyridine-3-carbaldehyde

The invention provides a preparation method of 6-chloro-4-hydroxypyridine-3-carbaldehyde. The final product, namely, 6-chloro-4-hydroxypyridine-3-carbaldehyde, is obtained through six-step reactions including ring closure, chlorination, etherification, reduction, oxidation and hydrolysis. The synthesis method is simple and easy to operate, a synthesis route is provided for product synthesis, theoretical and experimental bases are provided for industrial production, three wastes polluting the environment are not produced in the synthesis process, and the preparation method is very environment-friendly and suitable for large-scale industrial production. The synthesized product has high purity and yield and the production cost is low.

Structure-based design of substituted piperidines as a new class of highly efficacious oral direct renin inhibitors

A cis-configured 3,5-disubstituted piperidine direct renin inhibitor, (syn,rac)-1, was discovered as a high-throughput screening hit from a target-family tailored library. Optimization of both the prime and the nonprime site residues flanking the central piperidine transition-state surrogate resulted in analogues with improved potency and pharmacokinetic (PK) properties, culminating in the identification of the 4-hydroxy-3,5-substituted piperidine 31. This compound showed high in vitro potency toward human renin with excellent off-target selectivity, 60% oral bioavailability in rat, and dose-dependent blood pressure lowering effects in the double-transgenic rat model.

Diversity-oriented synthesis of 1-substituted 4-aryl-6-oxo-1,6- dihydropyridine-3-carboxamides.

A simple five-step diversity-oriented synthesis of 1-substituted 4-aryl-6-oxo-1,6-dihydropyridine-3-carboxamides was developed. Treatment of dimethyl 2-((dimethylamino)methylidene)-3-oxopentanedioate with twenty primary amines gave 1-substituted methyl 4-hydroxy-6-oxo-1,6-dihydropyridine-3- carboxylates. Transformation into the corresponding 4-tosyloxy and 4-chloro derivatives, followed by Suzuki-Miyaura arylations gave a series of eleven N-substituted methyl 4-aryl-6-oxo-1,6-dihydropyridine-3-carboxylates. Combinatorial screening was employed to establish suitable reaction conditions for Suzuki-Miyaura arylation of N-alkylpyridones. Hydrolysis of the esters followed by parallel solution-phase amidation of the corresponding carboxylic acids with primary and secondary amines furnished a library of seventeen final products.